{"id":"gr1014-cg-2-4","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T02:39:21.492Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123276,"model":"claude-sonnet-4-5-20250929"},"description":"GR1014-CG 2.4% is an investigational topical formulation developed by Graegis Pharmaceuticals Ltd currently in Phase 2 clinical trials. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indication at this stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT07192588","phase":"PHASE2","title":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Graegis Pharmaceuticals Ltd","startDate":"2024-07-26","conditions":"Radiodermatitis; Acute","enrollment":273}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":221198,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GR1014-CG 2.4%","genericName":"GR1014-CG 2.4%","companyName":"Graegis Pharmaceuticals Ltd","companyId":"graegis-pharmaceuticals-ltd","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}